#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP

• https://x.com/Yuz6Yusof/status/2063217963818266828/photo/1

ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte

• https://x.com/synovialjoints/status/2063218464748179676/photo/1

First head-to-head trial to show #PsA joint outcome superiority BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%. @RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD

• https://x.com/JihaRheum/status/2063218845842571488/photo/1

Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX

• https://x.com/synovialjoints/status/2062799915672031405/photo/1

🧬 Does spine vs knee enthesis differ immunologically? Translational scRNAseq study: YES! Spine produces more IL-23 but shows attenuated IL-17 response vs knee #POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ

• https://x.com/Nellziade/status/2062550503393828865/photo/1

🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA? YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts #OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN

• https://x.com/Nellziade/status/2062542859106910588/photo/1

Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+

Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY

• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1

22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026